Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults with Recurrent, Refractory or Progressive Osteosarcoma

Description

MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.

Conditions

Osteosarcoma

Talk to us

Study Overview

On this page

Study Details

Study overview

MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.

A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib As a Single Agent in Adolescents and Adults with Recurrent, Refractory or Progressive Osteosarcoma

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults with Recurrent, Refractory or Progressive Osteosarcoma

Condition
Osteosarcoma
Intervention / Treatment

-

Contacts and Locations

Cleveland

UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States, 44106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    12 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    MedPacto, Inc.,

    Study Record Dates

    2025-12